Research
Focused Science. Real Hope.
At the MVA Society, we don’t fund research for research’s sake. We fund it to find real treatments - and ultimately a cure - for Mosaic Variegated Aneuploidy (MVA).
MVA is one of the rarest conditions in the world, with fewer than 50 people currently diagnosed. Until recently, there were no studies, no drug trials, and no roadmap toward treatment. We're changing that by building the first-ever dedicated research programme for MVA.
Our goal is simple but ambitious:
To turn MVA from an untreatable diagnosis into a condition with real therapeutic options - within years, not decades.
We partner with world-leading scientists and clinicians to invest in targeted, high-impact research that’s practical, treatment-focused, and designed to move quickly.
Our Research Strategy
Strategic Focus on Treatable Pathways
We only fund research that has a clear route toward real-world treatments - including drug repurposing, cellular analysis, and genetic targeting. No vague science. Just focused progress.
Fast-Tracked by Data Rarity
With fewer than 50 known patients globally, we can coordinate research across the whole population - offering unprecedented access to data and potential breakthroughs.
As the MVA Society grows, we have been able to begin to capture patient data. With so few patients globally, the data we collect is invaluable to us. This data allows us to capture a high % of known patients and is key to propelling further research.
Guided by Experts
Our Medical Advisory Board includes world-renowned clinicians and researchers who guide every project - including Professor Anil Dhawan, a pioneer in paediatric liver medicine and rare disease, Professor Harry Leitch, a clinical geneticist at GOSH, Paediatric Consultant Sharon Jheeta who is a leading doctor within the Imperial Hospital group and Dr Ellie Seaby who specialises in general paediatrics and genetics.
Learn more about MVA research
Read more about the research being done on Mosaic Variegated Aneuploidy